Systematic pan-cancer analysis identified NCOA4 as an immunological and prognostic biomarker and validated in lung adenocarcinoma.

ABSTRACT:

Background

Cancer immunotherapy has revolutionized treatment, yet predicting patient responses remains challenging. The potential of nuclear receptor coactivator 4 (NCOA4) as a biomarker has been identified in different types of cancer. However, its role as an immunological and prognostic factor across cancers, particularly lung adenocarcinoma (LUAD), still needs to be fully understood. This study aims to address this gap by systematically analyzing NCOA4's expression and its correlation with clinical outcomes and immune responses in pan-cancer.

Objective

To evaluate NCOA4 as a prognostic biomarker and explore its association with immune microenvironments across different cancer types, specifically focusing on LUAD.

Methods

We comprehensively analyzed data from the CC

SUBMITTER: Wang A 

PROVIDER: S-EPMC12304365 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature